Britney Kepler
Psychiatric/Mental Health · Pittsburgh, PANPI 1942685110
Payments from drug & device makers
Across 819 payments — averaging $192.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$152K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$810
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$597
- Takeda Pharmaceuticals U.S.A., Inc.$415
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$131,28883%
- Travel & lodging$13,5019%
- Food & beverage$12,8398%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 483 | $151,567 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,173 |
| Alkermes, Inc. | 58 | $1,163 |
| Lundbeck LLC | 42 | $810 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $597 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $415 |
| Neurocrine Biosciences, Inc. | 20 | $316 |
| Johnson & Johnson | 14 | $261 |
| Corium, LLC | 13 | $241 |
| Ironshore Pharmaceuticals Inc. | 11 | $223 |
| Teva Pharmaceuticals USA, Inc. | 12 | $207 |
| Axsome Therapeutics, Inc. | 10 | $195 |
| Idorsia Pharmaceuticals US Inc | 6 | $106 |
| Neos Therapeutics, LP | 4 | $84 |
| Supernus Pharmaceuticals, Inc. | 5 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Tris Pharma Inc | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Almatica Pharma LLC | 2 | $36 |
| Eisai Inc. | 2 | $33 |
| Merck | 2 | $28 |
| Sage Therapeutics, LLC | 1 | $24 |
| Neuronetics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,776 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 43 | $59,689 |
| CaplytaLumateperone Tosylate | 30 | $47,060 |
| Abilify MaintenaAripiprazole | 17 | $41,431 |
| TrintellixVortioxetine Hydrobromide | 54 | $24,413 |
| QuviviqDaridorexant Hcl | 12 | $5,470 |
| Lisdexamfetamine Dimesylate | 18 | $5,108 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 64 | $3,665 |
| Paliperidone ErPaliperidone | 21 | $2,694 |
| Duloxetine Hcl | 97 | $1,720 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 35 | $1,582 |
| Lamotrigine ErLamotrigine | 15 | $1,533 |
| Nortriptyline Hcl | 23 | $1,439 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 43 | $1,237 |
| Perphenazine | 27 | $1,181 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $151,567 | $59,68943 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $597 | $47,06030 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,173 | $41,43117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $415 | $24,41354 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $106 | $5,47012 claims |
| Almatica Pharma LLCSertraline Hcl | $36 | $45958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Pittsburgh
- Amanda CieszynskiPittsburgh$8K
- Ashley WoodPittsburgh$7K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.